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INTRODUCTION
Antibiotics have been a cornerstone of medicine
for over 50 years. The beneﬁts they have provided
in preventing and treating bacterial infections are
inestimable. However, the usefulness of antibiotics
in many settings is under increasing threat from
the development of bacterial resistance. Indeed,
this is one of the most pressing concerns facing
health-care systems world-wide.
The world-wide problem of antibiotic resistance
is well documented. Since the early 1990s many
recommendations for its control have been pub-
lished by national and international bodies.
Whereas some countries have implemented pro-
grams for resistance control, in many others pro-
gress remains slow. The importance of a co-
ordinated international action is well recognized,
but this has seldom been achieved. In response to
this need, 23 leading experts came together in 2001
to form the International Forum on Antibiotic
Resistance (IFAR) with the view to serve as an
international think-tank to stimulate ongoing
debate and action on a global scale.
The Global White Paper on Bacterial Resistance
in Community-Acquired Respiratory Tract Infec-
tions is the ﬁrst document to be published by
IFAR. The paper focuses on bacterial resistance
in the community setting, where respiratory tract
infections are responsible for an enormous health-
care burden and represent the major driver of
antibiotic usage. Addressing resistance in the com-
munity presents particular challenges and
deserves particular attention. Furthermore, the
Global White Paper discusses issues relevant not
only to respiratory tract infections, but also to
infections per se as they occur in the hospital
and community.
The Global White Paper is not intended to add
to the plethora of recommendations for resistance
control. Rather it is an attempt to evaluate critically
our understanding of such issues as the:
 clinical impact of antibiotic resistance in respira-
tory tract infections;
 quality and applicability of resistance surveil-
lance data;
 factors driving resistance;
 role of the patient in resistance spread and con-
trol;
 challenges in applying resistance data to
antibiotic prescribing for respiratory tract in-
fections and the use of guidelines and
other prescribing support systems in this
process;
 extent to which national and international
recommendations have resulted in the imple-
mentation of co-ordinated interventions to con-
trol resistance and its effects;
 importance of audit and evidence for the effec-
tiveness of the various interventions recom-
mended.
The document is intended to be a useful
resource for all individuals involved in resistance
control and to stimulate discussion around these
challenging issues. The time has also come tomove
beyond simply describing the problem of antibio-
tic resistance toward the implementation of effec-
tive, internationally co-ordinated measures to
preserve one of our most valuable medical
resources.
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